Your browser doesn't support javascript.
loading
Effectiveness of benralizumab for allergic and eosinophilic predominant asthma following negative initial results with omalizumab.
Minami, Daisuke; Kayatani, Hiroe; Sato, Ken; Fujiwara, Keiichi; Shibayama, Takuo.
Afiliação
  • Minami D; Department of Respiratory Medicine National Hospital Organization Okayama Medical Center Okayama City Okayama Japan.
  • Kayatani H; Department of Respiratory Medicine National Hospital Organization Okayama Medical Center Okayama City Okayama Japan.
  • Sato K; Department of Respiratory Medicine National Hospital Organization Okayama Medical Center Okayama City Okayama Japan.
  • Fujiwara K; Department of Respiratory Medicine National Hospital Organization Okayama Medical Center Okayama City Okayama Japan.
  • Shibayama T; Department of Respiratory Medicine National Hospital Organization Okayama Medical Center Okayama City Okayama Japan.
Respirol Case Rep ; 7(1): e00388, 2019 Jan.
Article em En | MEDLINE | ID: mdl-30479771
ABSTRACT
A 64-year-old woman, who had presented with a 30-year history of refractory asthma, and been treated with anti-allergic drug therapy, inhaled corticosteroids, a long-acting beta-agonist, and a long-acting muscarinic antagonist. She had been characterized as an allergic, eosinophilic asthmatic. Although omalizumab was tried initially, it was found to be insufficient. We began treatment with benralizumab. The asthma symptom control and sinusitis were improved immediately. Benralizumab was effective for overlapping patient population following negative initial results with omalizumab.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article